Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IC7Fc
- Development stage
- Preclinical
- Lead developer
- Kinomedica
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal, Intravenous, Parenteral, Subcutaneous
01
Overview
IC7Fc is a designer chimeric cytokine and gp130 receptor agonist engineered to selectively activate regenerative and metabolic signaling pathways while avoiding the pro-inflammatory effects associated with interleukin-6 (IL-6) trans-signaling. It was constructed by replacing one gp130-binding site of IL-6 with the leukemia inhibitory factor receptor (LIFR)-binding site from ciliary neurotrophic factor (CNTF) and fusing it with the Fc domain of immunoglobulin G (IgG). IC7Fc promotes hepatocyte survival, tissue repair, and liver regeneration via the IL-22-STAT3 pathway, and has demonstrated therapeutic potential in preclinical models of alcohol-associated liver disease (ALD), type 2 diabetes, obesity, muscle atrophy, and atherosclerosis.
- Other names
- IC7-FcIC-7-FcIC 7-FcIC7-Fc fusion proteinIC-7-Fc fusion proteinIC 7-Fc fusion proteindesigner cytokine IC7Fcgp130 receptor ligand IC7Fcgp-130 receptor ligand IC7Fcgp 130 receptor ligand IC7Fc
02
Targets
IL-6R (Interleukin-6 receptor subunit alpha)IL6ST (Interleukin-6 receptor subunit beta)LIFR (Leukemia inhibitory factor receptor)
Beyond the preview
Go deeper on IC7Fc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IC7Fc.